about
Using nonhuman primates to model HIV transmissionNew generation humanized mice for virus research: comparative aspects and future prospectsExtreme Multidrug Resistant HIV-1 Protease with 20 Mutations Is Resistant to Novel Protease Inhibitors with P1′-Pyrrolidinone or P2-Tris-tetrahydrofuranEngineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancyDrug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.Sex hormones regulate tenofovir-diphosphate in female reproductive tract cells in culture.Reproductive assistance in HIV serodiscordant couples.Nonhuman primate models for HIV cure research.Estradiol regulation of nucleotidases in female reproductive tract epithelial cells and fibroblasts.Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20Global HIV/AIDS Clinical and Translational PharmacologyNondaily preexposure prophylaxis for HIV prevention.Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.Awareness of and willingness to use oral pre-exposure prophylaxis for HIV prevention among HIV-serodiscordant heterosexual couples: a cross-sectional survey in Xinjiang, China.Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis.Latest animal models for anti-HIV drug discovery.HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection.Multipurpose tenofovir disoproxil fumarate electrospun fibers for the prevention of HIV-1 and HSV-2 infections in vitro.Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.Awareness and use of pre-exposure and postexposure prophylaxes among Nigerian university students: Findings from a cross-sectional survey
P2860
Q26861425-73E624F7-5E4A-4003-8E4B-B24169025991Q27014786-6F1F3240-F546-4628-AFB2-C1CF19616151Q27677405-CDC9A50C-1E98-4587-8C45-AEB89DA2BD81Q28540419-0EBE9B2C-E9EB-403A-B557-9F023E3DDF66Q30249113-7DA9AFA1-FB3E-4E73-8E0D-C77E54210337Q33825769-D0119E93-803E-4F05-8671-90408C7330C5Q34311329-9C77B07B-527D-40F9-A5FC-ACD57337A7E0Q34407781-D8B0E74E-06C0-43BB-95EB-E9B2C8D1E38EQ34921423-FF1879F8-E4B4-470C-924C-59150CD4B052Q35033732-3B8848B7-2E4E-422F-8017-649D4063D9ABQ35794988-6CB1A255-EC02-479F-9E4C-0CD9DF0B37DBQ35909838-7210D8E2-BB4B-4B01-8650-FE03FEA24DD4Q36125023-FF21F118-564F-4FAE-88D3-6021E9072A7DQ36669377-9B9F5263-5802-4227-9CD7-FE2F553F0B44Q36727960-331F818B-6B0A-4D0A-8723-6BCCD3070A36Q36901505-F8D92FDF-DE44-4B9F-A758-32B86B7B8F88Q37017876-A7D5D3D4-8A64-4928-B598-ED4D02FAB834Q37023114-AD3DAC1F-C588-49E1-BCD5-22EFC2126A2CQ38263295-8B56D546-9381-429E-BA40-3B82E6608054Q39520219-942BEFDD-0E3B-4303-BCBD-2A1B9A54DA2BQ40086722-E08E3246-87D7-4783-AF0D-ED6E25390A4CQ40358789-F6815F4F-E2A6-49EE-A5CE-6B7ADB3C5AC9Q58759250-3569F63C-1AD4-439A-9A3B-FBA514061770
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
HIV prevention by oral preexposure prophylaxis.
@ast
HIV prevention by oral preexposure prophylaxis.
@en
type
label
HIV prevention by oral preexposure prophylaxis.
@ast
HIV prevention by oral preexposure prophylaxis.
@en
prefLabel
HIV prevention by oral preexposure prophylaxis.
@ast
HIV prevention by oral preexposure prophylaxis.
@en
P2860
P1476
HIV prevention by oral preexposure prophylaxis.
@en
P2093
Angela Kashuba
P2860
P304
P356
10.1101/CSHPERSPECT.A007419
P577
2012-03-01T00:00:00Z